Two new drugs currently look promising in treating late-staged kidney cancer, says experts at the European Cancer Congress. Both drugs in the experiment increased survival in trails.
These drugs are Nivolumab and Cabozantinib.
According to the European Society for Medical Oncology, ESMO, “Patients with advanced kidney cancer live for nearly twice as long without their disease progressing if they are treated with cabozantinib,”. The drug seems to stop the cancerous cell from working, acting as an, “‘on’ or ‘off’ switch”. Dr Alan Worsley from Cancer Research UK, explains that, “Cabozantinib, a targeted therapy, and nivolumab, an immunotherapy, fight cancer in very different ways, so making either available for use in the clinic will greatly expand the arsenal for clinicians to treat kidney cancer patients.”.
The July 2015 findings show that an estimated, progression-free, survival time for advanced clear cell kidney cancer suffers, that did not receive the drug cabozantinib, raised from 3.8 months, to 7.4 months who did receive the drug. It also reports that the percentage of patients whose tumours shrank, was 21% with the help of cabozantinib and 5% without.
Dr Worsley added that; “Advanced kidney cancer has been hard to treat for far too long and it has been particularly difficult to find drugs that work after first-line treatment has failed. The drugs tested in these two trials, both appear to work better than everolimus – one of the options available if the first treatment fails – and with fewer side-effects.”.
ESMO also explains that when kidney cancer is caught late and/or it has advanced into later stages, the outlook can be disappointing and result in a poor prognosis. “If it is caught early, the prognosis is good; 81% of patients with stage I disease, in which the tumour is confined to the kidney, survive for at least five years.” It continues; “However, when it has advanced, the prognosis is poor, with only around eight percent of patients with stage IV disease surviving for five years.”.
As stated on cancerresearchuk.org, more than 331,000 people are diagnosed with cancer each year in the UK, which is around 910 people every day. It claims that men are more likely to get cancer than women, “Each year, in the UK around 167,480 men are diagnosed and around 164,000 women.”. The findings also showed that as you get older, your chance of getting cancer increases, with nearly two thirds of all cancers, 63%, is diagnosed in people aged 65 and over.
According to the website’s section, ‘statistics and outlook for kidney cancer’, roughly 70% of people with kidney cancer will survive for a year or more after initial diagnosis. 60% will survive for 5 years or more, and 50% will survive for 10 years or more. Within the different types of kidney cancers, clear cell kidney cancer, or renal cell carcinoma, is one of the commonest kidney cancers, with 70-80% of patients diagnosed with this type of cancer.
The scientific co-chair of the congress, Professor Peter Naredi said that he felt, “excited over the advances” and that the results found will “most likely will be practice-changing”.